Jim Cramer's Wall Street Confidential, 11/02/07: Give Merck Another Shot

Recap of Jim Cramer’s comments on Wall Street Confidential, Friday November 2. Click on a stock ticker for more analysis:

Merck (MRK), Becton Dickinson (BDX), Cepheid (CPHD), Sanofi Aventis (SNY), Inverness Medical Innovations (IMA)
Merck, along with BDX and CPHD, is cashing in on vaccines, and while it was widely believed that vaccines were not worth the risk of class action suits, a lot of the bite has been taken out of plaintiffs' cases in the past few years, and vaccines now can make money. The revenue from Merck's papillomavirus vaccine is growing from $300 million to $4 billion over the next year, and its hepatits-B vaccine looks promising. Cramer's co-host, James Altucher commented, "I think if you want a solid 15%, maybe 20% a year for a long time, Merck is a great bet." While Merck has been beating its numbers, it is still only where it was a few years a go, which is a good entry point, according to Cramer, pointing out that SNY has seen 50% vaccine growth. Cramer also discussed the importance of diagnostics and recommended one of his holdings, Inverness Medical Innovations.

Seeking Alpha publishes a summary of Jim Cramer's stock picks every day including: Mad Money Recap, Lightning Round, Stop Trading and his Wall Street Confidential Picks.

Get Cramer's Picks by email -- it's free and takes only a few seconds to sign up.

Seeking Alpha is not affiliated with Jim Cramer, CNBC or TheStreet.com